Need Help?

Paediatric_and_adult_nasal_RNAseq___COVID19

Understanding infectivity, progression and disease severity of COVID-19 in children. Understanding infectivity, progression and disease severity of COVID-19 in children: It has been observed that COVID-19 infection appears to present with reduced clinical severity and prevalence within children (<18 years) compared to adults. This project as part of a national collaborative initiative seeks to answer this question. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001007718 Illumina NovaSeq 6000 268
EGAD00001015345 Illumina NovaSeq 6000 17
Publications Citations
Local and systemic responses to SARS-CoV-2 infection in children and adults.
Nature 602: 2022 321-327
142
Age-specific nasal epithelial responses to SARS-CoV-2 infection.
Nat Microbiol 9: 2024 1293-1311
0
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
ERJ Open Res 10: 2024 919-2023
0